Financial Performance - The company's operating revenue for Q3 2022 was ¥586,109,725.32, representing a 65.22% increase compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥138,407,977.41, a significant increase of 324.92% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥126,070,410.23, reflecting a 481.99% increase compared to the previous year[4] - Total operating revenue for Q3 2022 reached CNY 1,444,886,177.51, a 36.4% increase from CNY 1,059,099,172.23 in the same period last year[23] - Net profit for Q3 2022 was CNY 118,632,727.72, compared to a net loss of CNY 49,673,704.39 in Q3 2021, marking a significant turnaround[24] - Operating profit for the quarter was CNY 124,607,575.63, a recovery from an operating loss of CNY 32,511,354.52 in the previous year[23] - Basic and diluted earnings per share for Q3 2022 were CNY 0.3055, recovering from a loss of CNY 0.1356 per share in the same quarter last year[24] - The basic earnings per share for Q3 2022 was ¥0.3572, representing a 325.51% increase compared to the same period last year[4] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥6,769,148,386.26, which is a 3.33% increase from the end of the previous year[4] - The company's total assets as of September 30, 2022, amount to ¥6,769,148,386.26, an increase from ¥6,551,297,202.04 at the beginning of the year[20][21] - Current assets total ¥3,318,633,200.95, compared to ¥3,078,539,537.78 at the beginning of the year, reflecting a growth of approximately 7.8%[20] - Total liabilities increased to ¥3,426,177,374.22 from ¥3,300,170,250.21, indicating a growth of approximately 3.8%[21] - The company's equity attributable to shareholders increased to ¥3,340,187,434.71 from ¥3,248,600,124.87, reflecting an increase of about 2.8%[21] Cash Flow - The cash flow from operating activities for the first nine months of 2022 was ¥343,699,036.51, up 127.09% year-on-year[14] - Cash flow from operating activities generated CNY 343,699,036.51, a substantial increase from CNY 151,349,616.18 in the same quarter last year[25] - The company's investment activities generated a net cash flow of -¥625,520,712.28 for the first nine months of 2022, compared to -¥244,349,843.02 in the previous year[14] - Investment activities resulted in a net cash outflow of CNY 625,520,712.28, compared to a net outflow of CNY 244,349,843.02 in the previous year[25] - Financing activities generated a net cash inflow of CNY 40,666,662.64, a decrease from CNY 580,304,161.29 in Q3 2021[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,181[16] - The largest shareholder, Tao Jun, holds 27.03% of shares, amounting to 110,136,094 shares, with 42,150,000 shares pledged[16] - The company holds 14,536,516 shares in its repurchase account, accounting for 3.57% of the total share capital[17] - The company has a total of 1.76% of shares held by the state-owned entity, Great Wall Guorong Investment Management Co., Ltd.[17] Research and Development - The company's R&D expenses for the first nine months of 2022 were ¥9,503,019.60, an increase of 71.45% compared to the same period last year[12] - Research and development expenses increased to CNY 9,503,019.60, up 71.5% from CNY 5,542,665.57 in the prior year[23] Other Financial Metrics - The company's cash and cash equivalents decreased to ¥1,339,635,959.91 from ¥1,595,197,988.30, a decline of about 16.1%[20] - Short-term borrowings increased to ¥215,000,000.00 from ¥150,000,000.00, representing a rise of 43.3%[21] - The company's financial expenses for the first nine months of 2022 were ¥46,839,656.77, an increase of 86.29% year-on-year[12] - Total operating costs amounted to CNY 1,310,925,671.09, up 19.1% from CNY 1,100,766,880.41 year-over-year[23] Reporting and Governance - The third quarter report of Tianshui Zhongxing Mushroom Industry Technology Co., Ltd. is unaudited[27] - The board of directors meeting was held on October 11, 2022[28]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥858,776,452.19, representing a 21.92% increase compared to ¥704,358,946.32 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was -¥20,032,000.06, a decrease of 259.85% from ¥12,531,495.37 in the previous year[21]. - The net cash flow from operating activities was ¥133,532,517.30, up 22.91% from ¥108,645,002.15 in the same period last year[21]. - The total assets at the end of the reporting period were ¥6,713,869,999.98, an increase of 2.48% from ¥6,551,297,202.04 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 1.61% to ¥3,196,155,206.45 from ¥3,248,600,124.87 at the end of the previous year[21]. - The basic earnings per share were -¥0.0517, a decline of 246.05% compared to ¥0.0354 in the same period last year[21]. - The diluted earnings per share were also -¥0.0517, reflecting the same decline as the basic earnings per share[21]. - The weighted average return on net assets was -0.62%, down from 0.45% in the previous year[21]. - The company reported a net profit excluding non-recurring gains and losses of -¥1,963,568.98, an improvement of 87.10% from -¥15,224,715.34 in the same period last year[21]. Revenue and Sales - The company achieved operating revenue of ¥858,776,452.19, representing a year-on-year growth of 21.92%[29]. - The sales revenue from button mushrooms increased by 39.95% year-on-year, amounting to ¥430,857,838.37, while enoki mushrooms saw an 8.09% increase to ¥427,918,613.82[60]. - The total revenue for the first half of 2022 reached approximately 232.5 million CNY, with a net profit of around 47.1 million CNY[86]. - The company reported a total revenue of 40 million in the first half of 2022, reflecting a year-on-year increase of 15%[136]. - The company reported a revenue of 250 million CNY for the first half of 2022, representing a year-on-year increase of 15%[142]. Production and Operations - The company operates in the edible mushroom industry, focusing on research, cultivation, and sales, with production bases established in multiple provinces[29]. - The main products include enoki mushrooms and button mushrooms, which are known for their nutritional value and culinary uses[30][32]. - The company has a daily production capacity of 1,105 tons for edible mushrooms, with 745 tons for enoki mushrooms and 360 tons for button mushrooms, ranking among the industry leaders[51]. - The company has established production bases in multiple provinces, including Gansu, Shaanxi, Shandong, Jiangsu, Henan, Jilin, Sichuan, Anhui, and Hubei, allowing it to cover major markets nationwide[51]. - The company is adopting a factory-based production model to enhance efficiency and stability in supply chains[35]. Financial Management - The increase in financial expenses was attributed to higher interest costs from project loans and increased working capital borrowings compared to the previous year[33]. - The company reported a government subsidy income of ¥10,128,482.34, which is closely related to its normal business operations[25]. - The company has significant assets pledged as collateral for loans, totaling ¥824,457,545.97[69]. - The cash and cash equivalents decreased by 173.35% to -¥265,995,560.28, largely due to increased investment and loan repayments[58]. - The company raised a net amount of RMB 902.90 million from the issuance of 9.2 million convertible bonds at a face value of RMB 100 each[75]. Market and Competition - The company faces risks from increased competition in the edible mushroom market, which may lead to price declines due to rising supply from new entrants[87]. - Seasonal fluctuations in sales prices and profits are a concern, with the second quarter typically being a low-demand period for edible mushrooms[88]. - The edible mushroom industry is experiencing increased concentration, with a significant reduction in the number of production enterprises, from approximately 498 in 2018 to about 400 in 2019, a decrease of 19.68%[47]. Research and Development - The company focuses on independent research and development, supported by a biological engineering technology research center, which is recognized as a provincial-level enterprise technology center[40]. - Research and development expenses increased to CNY 4.59 million, up from CNY 3.10 million, indicating a focus on innovation[192]. - The company plans to invest 50 million CNY in R&D for new technologies in mushroom cultivation over the next year[142]. Environmental and Social Responsibility - The company has received no administrative penalties for environmental issues during the reporting period, indicating compliance with environmental regulations[109]. - The company has employed 90 workers from impoverished areas, with total wages amounting to CNY 1.9367 million, contributing to local economic development[110]. - The company has actively participated in poverty alleviation efforts, transitioning from "blood transfusion" to "blood production" by investing in local industries[109]. Shareholder and Governance - The company held two shareholder meetings during the reporting period, with participation rates of 36.89% and 37.04% respectively[97]. - The employee stock ownership plan includes 268 participants, with a total of 9 million shares held, representing 2.21% of the company's total equity[101]. - Key management personnel maintained their shareholdings throughout the reporting period, with the chairman and general manager each holding 1.5 million shares[101]. Future Outlook - The company expects a revenue growth forecast of 20% for the second half of 2022, driven by new product launches and market expansion strategies[137]. - The company plans to continue monitoring industry trends to assess the feasibility of ongoing projects amid a sluggish edible mushroom market[80]. - The company aims to leverage its brand and product quality to enhance market presence and pricing power amidst increasing competition[87].

天水众兴菌业科技股份有限公司 2022 年第一季度报告全文 股票代码：002772 股票简称：众兴菌业 公告编号：2022-037 债券代码：128026 债券简称：众兴转债 天水众兴菌业科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 488,191,571.56 | 395,772,820.20 | 23.35% | | 归属于上市公司股东的净利润（元） ...

Financial Performance - The total revenue for 2021 was 500 million RMB, representing a year-on-year increase of 15% compared to 2020[15]. - The net profit attributable to shareholders for 2021 was 80 million RMB, reflecting a growth of 20% from the previous year[15]. - The company's operating revenue for 2021 was CNY 1,556,146,725.49, representing a 4.92% increase compared to CNY 1,483,178,491.71 in 2020[20]. - In 2021, the company achieved total operating revenue of CNY 155,614.67 million, a year-on-year increase of 4.92%, while net profit attributable to shareholders decreased by 70.91% to CNY 5,496.80 million[44]. - The company reported a net profit of CNY 54.97 million, a significant decline of 70.91% compared to the previous year, yet it remains a leader in the industry[65]. - The company’s net profit for the year was CNY 54.32 million, despite significant cash outflows impacting operating cash flow[84]. Market Expansion and Strategy - The company plans to expand its market presence by entering two new provinces in 2022, aiming for a 10% increase in market share[15]. - The company aims to achieve a revenue target of 600 million RMB for 2022, indicating a growth forecast of 20%[15]. - The company is exploring potential mergers and acquisitions to enhance its supply chain efficiency and product offerings[15]. - The company is focused on expanding its edible mushroom production capabilities through strategic investments and partnerships[96]. - The company plans to enhance its production capacity with projects like the expansion of the Jiangsu subsidiary's mushroom cultivation facilities and the second phase of the Wuhui subsidiary's production project, which aims for an annual output of 40,000 tons of mushrooms[120]. Research and Development - Research and development expenses increased by 25% in 2021, focusing on new product innovations in the edible mushroom sector[15]. - The company is developing new mushroom strains, including a light yellow variety suitable for industrial cultivation, which is expected to open new market opportunities[80]. - The company is committed to improving its internal management and technical training to enhance mushroom cultivation technology[120]. - The company has introduced advanced technology and equipment in its production process, including temperature, humidity, and light control systems, to create an optimal growth environment for mushrooms[45]. Production and Capacity - The company has a daily production capacity of 1,105 tons, with a significant market share in the double-cultivated mushroom segment, which is becoming a new profit growth point[38]. - The company’s production capacity for edible mushrooms as of December 31, 2021, was 1,105 tons per day, with 745 tons for enoki mushrooms and 360 tons for button mushrooms, placing it at the forefront of the industry[58]. - The company has established 7 standardized production lines for double-cultivated mushrooms, with 6 already in operation, enhancing its competitive edge in the market[38]. Financial Management and Investments - The company raised a total of RMB 92,000 million through the issuance of 9.2 million convertible bonds, with a net amount of RMB 90,290 million after deducting issuance costs[104]. - The total investment amount for the reporting period reached ¥273,890,000, representing an increase of ¥28,446,019.42 or 862.84% compared to the previous year[94]. - The company has pledged fixed assets totaling ¥199,197,346.62 as collateral for long-term loans from Lanzhou Bank amounting to ¥92 million[93]. - The company has engaged in long-term borrowing activities, with various subsidiaries pledging assets for loans totaling over ¥2.9 billion[93]. Corporate Governance - The company has revised its governance structure to comply with relevant laws and regulations, ensuring better operational efficiency[121]. - The company has implemented a comprehensive internal control system to ensure compliance with relevant laws and regulations, maintaining high standards of corporate governance[146]. - The company maintains complete independence from its controlling shareholder in terms of assets, business operations, personnel, and financial management[147][151]. - The company has established a robust investor relations management system, ensuring timely and accurate communication with investors[145]. Sustainability and Environmental Practices - The company is committed to sustainable practices, utilizing waste mushroom substrate as fuel in its production process, thereby promoting a circular economy[59]. - The management team emphasized a focus on sustainability initiatives, aiming for a 30% reduction in carbon footprint by 2025[169]. - The company is addressing the risk of raw material price increases by optimizing its procurement strategies and maintaining stable supply channels[131]. Employee Management and Development - The total number of employees at the end of the reporting period was 5,588, with 459 in the parent company and 5,129 in major subsidiaries[182]. - The company has established a comprehensive salary system based on efficiency, fairness, and performance, with salaries consisting of basic, position, duty, performance wages, and various bonuses[183]. - The training system is tiered and focuses on enhancing employees' skills and business capabilities through onboarding, safety, and job training[184]. Challenges and Risks - The competitive landscape is intensifying, particularly for enoki mushrooms, leading to reduced profitability due to increased production capacity and market competition[37]. - The company faces risks from increased competition leading to price declines, and it plans to leverage its brand influence and product quality to mitigate this risk[126]. - Seasonal fluctuations in sales prices and profits pose a risk, but the company is diversifying its product offerings and extending its supply chain to reduce the impact of these fluctuations[127].

股票代码：002772 股票简称：众兴菌业 债券代码：128026 债券简称：众兴转债 公告编号：2021-108 天水众兴菌业科技股份有限公司 2021 年第三季度报告 天水众兴菌业科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）声明：保证季度报告中财务信 息的真实、准确、完整。 3、第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 比上年同期增减 | | 营业收入（元） | 354,740,225.91 | -11.43 ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 704,358,946.32, representing an increase of 11.22% compared to CNY 633,323,421.04 in the same period last year[21]. - The net profit attributable to shareholders decreased by 77.69% to CNY 12,531,495.37 from CNY 56,172,012.02 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY -15,224,715.34, a decline of 141.73% compared to CNY 36,487,398.51 in the same period last year[21]. - The net cash flow from operating activities was CNY 108,645,002.15, down 38.93% from CNY 177,907,967.99 in the previous year[21]. - Basic earnings per share fell by 78.45% to CNY 0.0354 from CNY 0.1643 in the same period last year[21]. - The operating cost increased by 25.50% to CNY 607,818,676.06, primarily due to increased production volume and rising raw material prices[59]. - The gross profit margin for the agricultural planting industry was 13.71%, down by 9.82% year-on-year[63]. Assets and Liabilities - Total assets increased by 9.15% to CNY 6,092,929,786.33 from CNY 5,581,944,186.22 at the end of the previous year[21]. - The net assets attributable to shareholders rose by 14.01% to CNY 3,111,507,572.32 from CNY 2,729,105,527.77 at the end of the previous year[21]. - The company's inventory stood at ¥278,655,082, which is 4.57% of total assets, showing a slight decrease of 0.10% compared to the previous year[68]. - Long-term borrowings rose to ¥1,750,765,650, accounting for 28.73% of total assets, an increase of 10.32% from 18.41% last year, driven by additional loans for daily operations and project construction[68]. Operational Developments - The company expanded its sales channels, with increased sales through fresh e-commerce, chain restaurants, and supermarkets[30]. - The company is advancing several projects, including the expansion of its mushroom cultivation facilities and the construction of a circular economy industrial park[30]. - The company is actively seeking new profit growth points, including a cash acquisition of 100% equity in Guizhou Maotai Town Shengjiao Liquor Co., Ltd.[31]. - The company has established production bases in multiple provinces, including Gansu, Shaanxi, Shandong, and others, ensuring coverage of major national markets[52]. Governance and Management - The company is committed to improving its governance structure and has completed the election of the fourth board of directors and supervisory board[32]. - The company has implemented a stable profit distribution policy to return value to shareholders, in accordance with the regulations set forth by the China Securities Regulatory Commission[110]. - The company has implemented an employee stock ownership plan with a scale of up to 9 million shares, with a purchase price of 1 RMB per share, to align employee interests with long-term company development[100]. Market and Competition - The company faces risks from increased competition in the edible mushroom industry, leading to potential price declines due to rapid capacity expansion[85]. - Seasonal fluctuations in sales prices and profits are a concern, with the second quarter typically being a low-demand period for mushrooms[86]. - The company is exploring opportunities for international expansion, particularly in Southeast Asian markets[144]. Environmental and Social Responsibility - The company has established a wastewater treatment facility with a capacity of 600 m³/d, utilizing A/O biological contact oxidation technology, ensuring that treated wastewater meets the Class I discharge standards of GB8978-1996[105]. - The company emphasizes social responsibility, aiming for sustainable development and actively contributing to local economic growth through its operations[109]. - The company practices sustainable development by recycling agricultural by-products and converting waste into organic fertilizers, thus promoting environmental protection[114]. Future Outlook - The company plans to leverage its circular economy advantages by utilizing waste materials for organic fertilizer production, contributing to sustainable practices[55]. - The company plans to expand its market presence by launching new products in the second half of 2021, targeting a 10% increase in market share[145]. - The company has set a performance guidance of 600 million yuan in revenue for the second half of 2021, indicating a positive outlook[144].

天水众兴菌业科技股份有限公司 2021 年第一季度报告全文 2021 年 04 月 1 天水众兴菌业科技股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陶军、主管会计工作负责人李敏及会计机构负责人（会计主管 人员）何文科声明：保证季度报告中财务报表的真实、准确、完整。 2 天水众兴菌业科技股份有限公司 2021 年第一季度报告 天水众兴菌业科技股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 395,772,820.20 | 366,584,750.64 | 7.96% | | 归属于上市公司股东的净利润（元） | 43,424,962.07 | 74 ...

Financial Performance - Operating revenue for the reporting period was ¥400,518,483.46, representing a year-on-year growth of 54.84%[9] - Net profit attributable to shareholders was ¥64,494,424.51, a significant increase of 735.94% compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥48,735,690.89, up 344.46% year-on-year[9] - Basic earnings per share for the reporting period was ¥0.1897, reflecting a growth of 765.61% compared to the same period last year[9] - The company's net profit for Q3 2020 reached CNY 121,080,149.93, a significant increase from CNY 39,857,373.16 in the same period last year, representing a growth of approximately 203%[67] - Operating profit for the third quarter was CNY 120,589,532.27, compared to CNY 39,262,088.17 in Q3 2019, indicating a year-over-year increase of about 207%[67] - The total comprehensive income for the third quarter was CNY 64,099,984.91, compared to a loss of CNY 10,248,452.42 in the previous year[60] Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,458,307,058.50, an increase of 8.88% compared to the end of the previous year[9] - The company's cash and cash equivalents at the end of the reporting period amounted to ¥1,295,672,063.69, an increase of 32.77% compared to the beginning of the year, primarily due to new bank borrowings[17] - The company’s total liabilities due within one year increased by 152.23% to ¥376,137,285.19, attributed to an increase in borrowings due within one year according to the repayment plan[17] - The company's total liabilities increased to CNY 2,803,590,262.28 from CNY 2,410,791,004.22 year-over-year, indicating a rise in financial obligations[52] - Total liabilities reached CNY 2,410,791,004.22, with current liabilities at CNY 404,231,897.58 and non-current liabilities at CNY 2,006,559,106.64[82] Cash Flow - The net cash flow from operating activities was ¥25,075,542.56, down 46.19% year-on-year[9] - The cash inflow from operating activities was CNY 1,091,254,256.00, an increase from CNY 847,785,980.63 in the previous period, representing a growth of approximately 29.5%[74] - The net cash flow from financing activities was CNY 276,749,194.02, a significant drop from CNY 703,286,653.44, representing a decline of approximately 60.7%[75] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,812[13] - The largest shareholder, Tao Jun, holds 29.95% of the shares, with 110,136,094 shares pledged[13] - The company repurchased a total of 14,536,516 shares in the second phase of the buyback program, with a total transaction amount of approximately ¥101 million, at a maximum price of ¥8.66 per share and a minimum price of ¥6.13 per share[29] Research and Development - Research and development expenses for the first nine months of 2020 totaled ¥5,119,701.83, a significant increase of 96.07% year-on-year, reflecting higher R&D investments[19] - Research and development expenses for Q3 2020 were CNY 1,753,984.18, up from CNY 1,039,642.72 in the previous year, highlighting a focus on innovation[58] Investment Activities - The company’s investment income for the first nine months of 2020 was ¥2,076,181.65, a decrease of 85.56% year-on-year, primarily due to recognized investment losses from joint ventures and associates[19] - The net cash flow from investing activities for the first nine months of 2020 was -¥143,722,560.37, an improvement from -¥294,335,146.35 in the same period last year, primarily due to reduced investment expenditures on ongoing projects[20] Corporate Governance - The company has implemented its first employee stock ownership plan to align employee interests with long-term corporate development, enhancing overall competitiveness[23] - There are no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[29] Future Outlook - The company is exploring new strategies for market expansion and product development in the upcoming quarters[39] - The company has indicated plans for potential mergers and acquisitions to enhance its market position[39] - The company is committed to ongoing research and development of new technologies to improve operational efficiency[39]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥633,323,421.04, representing a 24.41% increase compared to ¥509,043,588.29 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was ¥56,172,012.02, up 13.28% from ¥49,585,805.88 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was ¥36,487,398.51, an increase of 11.63% compared to ¥32,686,406.68 in the same period last year[18]. - The basic earnings per share increased by 17.61% to ¥0.1643 from ¥0.1397 in the previous year[18]. - The total assets at the end of the reporting period were ¥5,366,196,338.44, a 7.05% increase from ¥5,012,915,611.36 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company decreased by 0.57% to ¥2,584,723,600.99 from ¥2,599,482,132.26 at the end of the previous year[18]. - The net cash flow from operating activities was ¥177,907,967.99, showing a slight increase of 0.53% compared to ¥176,970,763.60 in the same period last year[18]. - The weighted average return on net assets was 2.16%, up from 1.87% in the previous year, indicating improved profitability[18]. Production and Sales - The company has established production bases for edible fungi in multiple provinces, including Gansu, Shaanxi, Shandong, Jiangsu, Henan, Jilin, Sichuan, Anhui, and Hubei[26]. - The main products are enoki mushrooms and button mushrooms, with enoki mushrooms accounting for over 80% of production and sales[27]. - The company increased edible mushroom production due to the commissioning of new bases in Xinxiang and Anhui, leading to higher output compared to the previous year[28]. - The company has a daily production capacity of 965 tons of edible mushrooms, with enoki mushrooms at 745 tons and button mushrooms at 220 tons, ranking among the industry leaders[42]. - The company’s market share further consolidated and increased, with sales volume growing approximately 20% compared to the same period last year[53]. - The sales revenue from the double mushroom segment surged by 93.03%, amounting to ¥178,630,293.59, compared to ¥92,539,437.79 in the previous year[58]. - The production of edible mushrooms increased by 24.51%, primarily due to the commencement of operations at the Xinxiang Xinghe Phase II and Anhui Zhongxing projects[56]. Investment and Financing - The company has completed the non-public offering of funds, raising a total of RMB 1,176.45 million, with RMB 992.76 million utilized by the reporting period[79]. - The company reported a total of CNY 201.04 million raised from public offerings, with CNY 151.99 million already utilized[77]. - The company has invested CNY 2.67 million from the raised funds during the reporting period[77]. - The company has a total of CNY 663 million in financial assets, with a fair value change of CNY 5.07 million[73]. - The company has a total of 10 subsidiaries, with varying levels of profitability and contributions to the overall financial performance[96]. Risk Management - The company does not foresee any significant adverse risks affecting its production, operation, financial status, or sustainable profitability[5]. - The company faces risks related to product quality instability due to new strains and changes in cultivation media, which may affect profitability[98]. - The company anticipates increased competition in the edible mushroom industry, leading to potential price declines due to rising supply without corresponding demand growth[100]. - The company has established a comprehensive quality control system to mitigate food safety risks, but potential contamination during various stages of production remains a concern[102]. - Fluctuations in raw material prices, particularly for corn cobs and rice bran, have affected production costs, with ongoing volatility expected due to increased downstream demand and extreme weather[104]. Corporate Governance and Compliance - The company has not experienced any significant litigation or arbitration matters during the reporting period[114]. - There were no media inquiries or widespread doubts regarding the company during the reporting period[115]. - The company did not face any penalties or rectification issues during the reporting period[116]. - The company and its controlling shareholders have no records of dishonesty or unfulfilled court judgments[117]. - The company has not made any acquisitions or significant investments in new subsidiaries during the reporting period[97]. Social Responsibility and Community Engagement - The company issued a living subsidy of CNY 10,000 per quarter to ten households in difficulty, totaling CNY 20,000 during the reporting period[153]. - The company invested CNY 83,000 to build a pavilion for villagers in the targeted poverty alleviation area, enhancing both material and cultural support[154]. - The company plans to continue increasing investments in impoverished areas to drive poverty alleviation through industry, prioritizing employment for impoverished households[155]. - The company has actively fulfilled its social responsibility by creating job opportunities for local farmers and promoting the development of related industries[152]. Environmental Compliance - The wastewater treatment facility has a processing capacity of 600 m³/d, utilizing the A/O biological contact oxidation process, and currently operates normally[146]. - The company achieved compliance with the GB8978-1996 Class I standard for wastewater discharge, ensuring that all wastewater is treated before release[146]. - The company is committed to adhering to environmental protection laws and regulations[147]. - The concentration of COD in the treated wastewater was recorded at 76 mg/L, with an annual discharge of 5.99 tons, which is below the permitted limit[145]. Shareholder and Capital Management - The company completed a share repurchase plan, acquiring a total of 14,536,516 shares, approximately 3.95% of the total share capital, for a total amount of CNY 101,002,394.57[157]. - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares to all shareholders, with the remaining undistributed profits carried forward to the next year[163]. - The total number of ordinary shareholders at the end of the reporting period was 34,358[177]. - Major shareholder Tao Jun holds 29.95% of the shares, totaling 110,136,094 shares, with 27,534,024 shares pledged[177]. Future Outlook - Future guidance indicates a continued emphasis on increasing production capacity and improving operational efficiency to meet growing demand[141]. - The company plans to launch new products in the upcoming quarters, aimed at capturing a larger market share[141]. - The management remains optimistic about achieving its financial targets for the year, despite market challenges[141].

天水众兴菌业科技股份有限公司 2020 年第一季度报告全文 天水众兴菌业科技股份有限公司 2020 年第一季度报告 2020 年 04 月 1 天水众兴菌业科技股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 公司负责人陶军、主管会计工作负责人李敏及会计机构负责人（会计主管 人员）董建军声明：保证季度报告中财务报表的真实、准确、完整。 2 天水众兴菌业科技股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 366,584,750.64 | 307,543,510.25 | 19.20% | | 归属于上市公司股 ...